In contrast, although the HGF antibody rilotumumab (AMG102) has shown some anti-tumor effects in preclinical trials, its combination with bevacizumab did not significantly inhibit tumor growth and resulted in high toxicity.148. This evidence concerns the gene HGF and neoplasm.